Allaxys Communications --- Transponder V --- Allaxys Forum 1
Alternative Methoden => Homöopathie => Topic started by: ama on June 30, 2024, 06:30:21 AM
-
Before we look at the Indian homeopathic azzholes let me first show you something:
https://x.com/DaniBeckman/status/1806483203924041882
[*QUOTE*]
---------------------------------------------------------------------
Danielle Beckman @DaniBeckman
Not 👏Brain 👏Fog👏
This is a photo of a neuron exploding with #SARSCoV2.
This is Brain Damage.
Image
(https://pbs.twimg.com/media/GRHpwLtbgAAPi6a?format=jpg&name=900x900)
https://pbs.twimg.com/media/GRHpwLtbgAAPi6a?format=jpg&name=900x900
2:22 AM · Jun 28, 2024
255.3K Views
---------------------------------------------------------------------
Danielle Beckman @DaniBeckman
Jun 28
How many groups have to show that SARS-Cov-2 infects the brain, replicates inside neurons, and disrupts synapses? How long will scientists and patients continue to be ignored?
#neuroCovid
Image
(https://pbs.twimg.com/media/GRHreCQbUAA0JZR?format=jpg&name=900x900)
https://pbs.twimg.com/media/GRHreCQbUAA0JZR?format=jpg&name=4096x4096
---------------------------------------------------------------------
Sharky @Mr_Landshark
Jun 28
So it’s brain damage that doesn’t heal ?
---------------------------------------------------------------------
Danielle Beckman @DaniBeckman
Jun 28
Exactly. Neurons are nonrenewable cells, but the system can compensate (to a certain degree) depending on several factors. The brain is usually very resilient, but with viruses, we don't really know how much.
---------------------------------------------------------------------
[*/QUOTE*]
SarsCov2 causes brain damage.
This brain damage does NOT heal.
This brain damage is a lasting damage.
SarsCoV2 enters the brain and stays there. It does not go away.
SarsCoV2 is a lethal enemy to every mammal on earth.
Now let's look at what the Indian homeopathic azzholes claim. They are parasites which prey on unsuspecting patients.
The Indian homeopathic azzholes are damned pieces of shit and shall go to hell with their fraud.
https://karger.com/cmr/article-abstract/31/1/1/870353/Individualized-Homeopathic-Medicines-in-the?redirectedFrom=fulltext
[*QUOTE*]
---------------------------------------------------------------------
S. Karger AG
Complementary Medicine Research
Volume 31, Issue 1
February 2024
Issue Cover
Research Articles| November 26 2023
Individualized Homeopathic Medicines in the Treatment of Post-COVID-19 Fatigue in Adults: Single-Blind, Randomized, Placebo-Controlled Trial
Topic Article Package: Topic Article Package: Coronavirus (COVID-19)
Subject Area: Further Areas , General Medicine
Sangita Saha;
Rakesh Singh;
Ishika Mani;
Kalyan Chakraborty;
Paulami Sarkar;
Subhranil Saha;
Abhijit Rana;
Rajat Chattopadhyay
Complement Med Res (2024) 31 (1): 1–9.
https://doi.org/10.1159/000535279
Article history
PubMed:
38008074
Abstract
Introduction:
The coronavirus disease 2019 (COVID-19) is leading to unknown and unusual health conditions that are challenging to manage. Post-COVID-19 fatigue is one of those challenges, becoming increasingly common as the pandemic evolves, as it impairs the quality of life of an individual. This trial attempts to identify the preliminary evidence of the efficacy of individualized homeopathic medicines (IHMs) against placebos in the treatment of post-COVID-19 fatigue in adults.
Methods:
A 3-month, single-blind, randomized, placebo-controlled, parallel-arm trial was conducted at the outpatient department of The Calcutta Homoeopathic Medical College and Hospital, India. Sixty participants were randomized in a 1:1 ratio to receive either IHMs (n = 30) or identical-looking placebos (n = 30). The primary and secondary outcome measures were the Fatigue Assessment Scale (FAS) and Outcome in Relation to Impact on Daily Living (ORIDL), respectively, measured every month, for up to 3 months. Comparative analysis was carried out on the intention-to-treat sample to detect group differences.
Results:
Group differences in both the primary (FAS total: F1, 58 = 14.356, p < 0.001) and secondary outcomes (ORIDL: F1, 58 = 210.986, p < 0.001) after 3 months favored IHMs against placebos. Lycopodium clavatum (11.7%), sulfur (11.7%), Arsenicum album (10%), and Thuja occidentalis (10%) were the most frequently indicated medicines. No harm, unintended effects, homeopathic aggravations, or any serious adverse events were reported from either of the groups.
Conclusion:
IHMs produced significantly better effects than placebos in the treatment of post-COVID-19 fatigue in adults. Definitive robust trials may be undertaken to confirm the findings.
Journal Section:
Research Article / Originalarbeit
Keywords:
COVID-19, Fatigue, Homeopathy, Placebo, Randomized controlled trial
Supplementary Material for: Individualized homeopathic medicines in the treatment of post-COVID-19 fatigue in adults: A single-blind, randomized, placebo-controlled trial
Showing 1/3: Supplementary material-Supplementary_files.pdf
343 views
0 shares
53 downloads
CONSORT 2010 checklist
Page
1
Supplementary file
1
:
CONSORT 2010 checklist of information to include when reporting a randomised trial
*
Section/Topic
Item
No
Checklist
item
Reported on
page
No
Title and abstract
1
a
Identification as a randomi
s
ed trial in the title
1
1
b
Structure
d summary of trial des
ign, me
thods, results, and conclusions
(
parallel, factorial)
including allocation ratio
4
3b
Important changes to methods after trial commencement (
such as
eligibility criteria), with reasons
NA
Participants
4a
Eligibility criteria
f
or participants
5
4b
Settings and locations where the data were collected
4
Interventions
5
The interventions for each group with sufficient details to allow replication, including how and when they were
actually administered
5
-
6
Ou
tcomes
6
a
Comple
te
ly d
efined pre
-
specified primary and secondary outcome measures, including how and
when they
were assessed
6
6
b
Any changes to trial outcomes after the trial commenced
,
with reasons
NA
Sample size
7
a
How sample size was determined
6
7
b
When applic
ab
le, ex
planation of any interim analyses and stopping guidelines
NA
Randomisation:
Sequence
generation
8
a
Method used to generate the random allocation
sequence
6
8
b
Type of randomi
s
ation; details of any restriction (
such as
blocking and block size)
6
Allocation
concealment
mechanism
9
Mechanism used to implement the random allocati
on sequence (
such as
sequentially numbered containers),
describing any steps taken to conceal the sequence until interventions were assigned
6
Implementation
10
Who generated the random allocation sequence, who enrolled participants, and who assigned p
ar
ticipants to
interventions
6
Blinding
11
a
If done, who was blinded after assignment to interventions (
for example,
participants, care providers,
those
6
CONSORT 2010 checklist
Page
2
assessing outcomes) and how
11
b
If relevant, description of the similarity of interventions
5
-
6
Sta
ti
stical methods
12
a
Statistical methods used to compare groups for
primary and secondary outcomes
6
-
7
12b
Methods for additional analyses, such as subgroup analyses and adjusted analyses
NA
Results
Participant flow (
a
diagram is strongly
recommended
)
13
a
For each group, the numbers of participants who were randomly assigned, received intended
treatment, and
were analysed for the primary outcome
7
13
b
For each group, losses and exclusions after randomi
s
ation,
together with reasons
7
Re
cruitm
ent
14
a
Dates defining the periods of recruitment and follow
-
up
7
14b
Why the trial ended or was stopped
NA
Baseline data
15
A table showing baseline demographic and clinical characteristics for each group
Table 1
Numbers analy
s
ed
16
F
or e
ach group, n
umber of participants (denominator) included in each analysis and whether the analysis was
by original assigned groups
7
Outcomes and
estimation
17
a
For each primary and secondary outcome, results for each group, and the estimated effect
s
ize
and its
pre
cision (
such as
95% confidence interval)
7
-
8
17b
For binary outcomes, presentation of both absolute and relative effect sizes is recommended
NA
Ancillary analyses
18
Results of any other analyses performed, including subgroup analyses a
n
d ad
justed ana
lyses, distinguishing
pre
-
specified from exploratory
NA
Harms
19
All important harms or u
nintended effects in each group
(
for specific guidance see CONSORT for
harms
)
8
Discussion
Limitations
20
Trial limitations, addressing sources of
po
tent
ial bia
s, imprecision, and, if relevant, multiplicity of analyses
8
Generali
s
ability
21
Generali
s
ability (external validity, applicability) of the trial findings
8
Interpretation
22
Interpretation consistent with results, balancing benefits a
nd h
ar
ms, and
considering other relevant evidence
9
Other information
Registration
23
Registration number and name of trial registry
4
Protocol
24
Where the full trial protocol can be accessed, if available
4
Funding
25
Sources of funding
and other
s
uppor
t (
suc
h as
supply of drugs)
,
role of funders
10
*We strongly recommend
reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all t
he items. If relevant, we also
recommend reading CONSORT extensions for cluster randomised trials, non
-
inferiority and equivalence
trials, non
-
pharmacological treatments, herbal interventions, and pragmatic trials.
Additional extensions are forthcoming: for those and for
up
-
to
-
date
references relevant to this checklist, see
www.consort
-
statement.org
.
1 / 3
figshare
References
1.Chippa
V
, Aleem
A
, Anjum
F
Post-acute coronavirus (COVID-19) syndrome
Treasure Island (FL)
StatPearls Publishing
. 2023
.
Google Scholar
2.Baig
AM
. Deleterious outcomes in long-hauler COVID-19: the effects of SARS-CoV-2 on the CNS in chronic COVID syndrome
. ACS Chem Neurosci
. 2020
;11
(24
):4017
–20
.
Google Scholar
Crossref
PubMed
3.Rodriguez-Sanchez
I
, Rodriguez-Mañas
L
, Laosa
O
. Long COVID-19: the need for an interdisciplinary approach
. Clin Geriatr Med
. 2022
;38
(3
):533
–44
.
Google Scholar
Crossref
PubMed
4.Kamal
M
, Abo Omirah
MA
, Hussein
A
, Saeed
H
. Assessment and characterisation of post-COVID-19 manifestations
. Int J Clin Pract
. 2021
;75
(3
):e13746
.
Google Scholar
Crossref
PubMed
5.Malik
P
, Patel
K
, Pinto
C
, Jaiswal
R
, Tirupathi
R
, Pillai
S
et al. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL): a systematic review and meta-analysis
. J Med Virol
. 2022
;94
(1
):253
–62
.
Google Scholar
Crossref
PubMed
6.SEMG encuesta COVID-19 persistente. Presentación de Resultados
. 2020
.
7.Sykes
DL
, Holdsworth
L
, Jawad
N
, Gunasekera
P
, Morice
AH
, Crooks
MG
. Crooks MG post-COVID-19 symptom burden: what is long-COVID and how should we manage it
. Lung
. 2021
;199
(2
):113
–9
.
Google Scholar
Crossref
PubMed
8.A clinical case definition of post-COVID-19 condition by a Delphi consensus
. 2023
. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 [Accessed 2023 Aug 23].
9.Michielsen
HJ
, De Vries
J
, Van Heck
GL
. Psychometric qualities of a brief self-rated fatigue measure the fatigue assessment scale
. J Psychosom Res
. 2003
;54
(4
):345
–52
.
Google Scholar
Crossref
PubMed
10.Close
SC
. VII: susceptibility, reaction, and immunity
. In. The genius of Homoeopathy: lectures and essays on homoeopathic philosophy
New Delhi
B. Jain Publishers (P) Ltd
. 2005
. p. 76
86
.
Google Scholar
11.Reilly
D
, Mercer
SW
, Bikker
AP
, Harrison
T
. Outcome related to impact on daily living: preliminary validation of the ORIDL instrument
. BMC Health Serv Res
. 2007
;7
:139
.
Google Scholar
Crossref
PubMed
12.Schulz
KF
, Altman
DG
, Moher
D
CONSORT Group
. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials
. Open Med
. 2010
;4
(1
):e60
–8
.
Google Scholar
PubMed
13.Dean
ME
, Coulter
MK
, Fisher
P
, Jobst
K
, Walach
H
. Reporting data on homeopathic treatments (RedHot): a supplement to CONSORT
. Homeopathy
. 2007
;96
(1
):42
–5
.
Google Scholar
Crossref
PubMed
14.Rathi
A
, Jadhav
SB
, Shah
N
. A randomized controlled trial of the efficacy of systemic enzymes and probiotics in the resolution of post-COVID fatigue
. Medicines
. 2021
;8
(9
):47
.
Google Scholar
Crossref
PubMed
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
Sign in
Don't already have an account? Register
Individual Login
LOGIN TO MY KARGER
Institutional Login
Access via Shibboleth and OpenAthens
Access via username and password
Digital Version
Pay-Per-View Access
$39.00
BUY THIS Article
1 Karger Article Bundle Token
$150
Buy Token
Rental
This article is also available for rental through DeepDyve.
Article has an altmetric score of 2
View Metrics
0
0
0
0
Smart Citations
0
0
0
0
Citing PublicationsSupportingMentioningContrasting
View Citations
See how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Email alerts
Online First Alert
Latest Issue Alert
Citing articles via
Google Scholar
Latest
Most Read
Most Cited
What a Study Is about Should Be Clear
Nurturing Hope: Reproductive Outcomes with Sinosomatics following Unsuccessful in vitro Fertilization Attempts
Society Bulletins · Gesellschaftsmitteilungen
Low Inter-Rater Reliability and Reproducibility of Neck Reflex/“Adler-Langer” Points in Neural Therapy Diagnostics but Increased Pressure Pain Threshold after Therapy: Results of a Randomized Controlled Observer-Blind Trial
Acupuncture Point Selection Patterns for Chemotherapy-Induced Nausea and Vomiting: A Data Mining Analysis
Suggested Reading
Efficacy of Individualized Homeopathic Medicines in the Treatment of Cervical Spondylosis: A Double-Blind, Randomized, Placebo-Controlled Trial
Complement Med Res (February,2023)
Individualized Homeopathic Medicines in the Treatment of Psoriasis Vulgaris: Double-Blind, Randomized, Placebo-Controlled Trial
Complement Med Res (June,2023)
Prespecified Homeopathic Medicines in the Prevention of Confirmed and Suspected Cases of COVID-19: A Community-Based, Double-Blind, Randomized, Placebo-Controlled Prophylaxis Trial
Complement Med Res (January,2024)
Individualized Homeopathic Medicines in the Treatment of Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled, Pilot Trial
Complement Med Res (March,2021)
Online ISSN 2504-2106 Print ISSN 2504-2092
ABOUT US
Company
People & Organization
Newsroom
Careers
Stay Up-to-Date
Regional Offices
Community Voice
Karger International
S. Karger AG
P.O Box, CH-4009 Basel (Switzerland)
Allschwilerstrasse 10, CH-4055 Basel
Tel: +41 61 306 11 11
Fax: +41 61 306 12 34
Contact: Front Office
---------------------------------------------------------------------
[*/QUOTE*]